CME Information
A CME-certified enduring webcast focusing on highlights from Digestive Disease Week and the 76th American College of Gastroenterology 2008 Annual Scientific Meeting.
Target audience
This CME-certified activity has been developed for gastroenterologists who have an interest in optimizing the management of patients with Crohn's disease.
Learning objectives:
Upon completion of this activity participants should be able to:
- Summarize the latest concepts in the diagnosis, evaluation and treatment of patients with Crohn’s disease
- Discuss how recently presented data will advance current clinical practice in the management of Crohn’s disease
- Explain how to integrate the best available evidence with expert clinical opinion to achieve a new level of best practice.
Syllabus disclosure statement
In direct response to the September 2004 Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, CME Consultants issued a conflict of interest policy dated January 2, 2005. The policy states that the disclosure of potential financial conflicts of interest within the last 12 months must be made and resolved prior to date of the CME/CE activity where commercial support grants are to be used to fund the activity. The following conflicts have been managed and resolved through CME Consultants’ Independent Review Committee. Our intent is to assist learners in assessing the potential for bias in information that is presented during this CME/CE activity.
The faculty is also aware it is their responsibility to inform the audience if discussion of any non-FDA approved uses of pharmaceuticals, medical equipment, prostheses, etc. will be included in their presentation.
| Faculty Name | Company | Relationship |
| Stephen B. Hanauer | Abbott Laboratories Amgen Asahi AstraZeneca Bristol-Myers Squibb Centocor, Inc. ChemoCentryx Elan Pharmaceuticals, Inc. Ferring Genentech, Inc. GlaxoSmithKline Millennium Pharmaceuticals, Inc. Novartis Otsuka Pharmacia Protein Design Labs Procter & Gamble Prometheus Laboratories, Inc. Salix Pharmaceuticals, Inc. Shire Pharmaceuticals Solvay Targacept Teva Therakos UCB, Inc. |
Consultant, Grant Support, Honoraria Consultant Consultant, Grant Support Consultant Consultant Consultant, Grant Support, Honoraria Consultant, Grant Support Consultant, Grant Support Consultant, Grant Support, Honoraria Consultant, Grant Support Consultant Consultant Consultant Consultant, Grant Support Consultant, Grant Support Consultant, Grant Support Consultant, Grant Support, Honoraria Consultant, Grant Support, Honoraria Consultant, Grant Support, Honoraria Consultant, Grant Support Consultant Consultant Consultant Consultant Consultant, Grant Support, Honoraria |
Jean-Frederic Colombel |
Abbott Laboratories |
Consultant, Advisory Board, Speaker Consultant, Advisory Board Consultant, Advisory Board, Speaker, Research Grant Consultant, Advisory Board Consultant, Advisory Board Consultant, Advisory Board Consultant, Advisory Board, Speaker Consultant, Advisory Board Consultant, Advisory Board Consultant, Advisory Board, Speaker Speakers Fee, Research Grant Consultant, Advisory Board Consultant, Advisory Board Consultant, Advisory Board Consultant, Advisory Board Consultant, Advisory Board, Speaker Consultant, Advisory Board, Speaker Consultant, Advisory Board, speaker Consultant, Advisory Board Consultant, Advisory Board Consultant, Advisory Board Consultant, Advisory Board Consultant, Advisory Board, Speaker |
Remo Panaccione |
Abbott Laboratories AstraZeneca Axcan Pharma, Inc. Bristol-Myers Squibb Byk Solvay Canada, Inc. Centocor, Inc. Elan Pharmaceuticals, Inc. Ferring Pharmaceuticals, Inc. GlaxoSmithKline Janssen Pharmaceutica, Inc. Millennium Pharmaceuticals Procter & Gamble Prometheus Laboratories, Inc. Schering-Plough Corporation Shire Pharmaceuticals UCB, Inc. |
Advisory Board, Consultant, Speakers Bureau, Support |
The planners, managers and anyone in a position to control the content of CME activities are also required to report any conflicts of interest. The following conflicts have been managed and resolved through CME Consultants’ Independent Review Committee.
| Name of Planner or Manager | Company and Relationship |
| Samantha Mattiucci, PharmD, CME Consultants | Nothing to disclose |
| Joyce M. Anderson, Project Director, CME Consultants | Nothing to disclose |
| Sarah Diffen, Associate Project Director, Strategic Consultants International | Nothing to disclose |
| Alison Howe, Managing Director, Strategic Consultants International | Nothing to disclose |
Certification Statement
This Activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of CME Consultants and Strategic Consultants International (SCI). CME Consultants is accredited by the ACCME to provide continuing medical education for physicians.
CME Consultants designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The contents of some CME activities may contain discussions of non-approved or off-label uses of some of the agents mentioned. Please consult the full prescribing information for full disclosure of approved uses.
This activity should take approximately 90 minutes to complete, including the time to take the post-test and complete the evaluation.
This activity was made possible through an educational grant provided by UCB, Inc.
Date of original release: December 4, 2008
Valid for credit through: December 4, 2009